Loading...
BVMF
BLAU3
Market cap460mUSD
Jun 04, Last price  
14.60BRL
1D
0.62%
1Q
16.71%
IPO
-62.91%
Name

Blau Farmaceutica SA

Chart & Performance

D1W1MN
P/E
11.94
P/S
1.48
EPS
1.22
Div Yield, %
2.50%
Shrs. gr., 5y
4.08%
Rev. gr., 5y
12.41%
Revenues
1.75b
+27.81%
383,451,000430,933,000617,658,000782,164,000977,500,0001,181,804,0001,366,407,0001,406,909,0001,372,633,0001,754,376,000
Net income
217m
-13.05%
23,062,00032,333,000103,128,000123,253,000200,238,000254,330,000325,222,000363,368,000249,809,000217,206,000
CFO
507m
+169.70%
17,061,00045,679,000126,632,00082,532,000221,290,000226,515,000153,976,000171,903,000188,060,000507,203,000
Dividend
Sep 27, 20240.08442108 BRL/sh

Profile

Blau Farmacêutica S.A., a pharmaceutical company provides private label drugs in Brazil, Argentina, Colombia, the United States, Ecuador, Peru, and Uruguay. The company's medications cover various therapeutic classes, such as immunology, hematology, oncology, nephrology, specialties, and antibiotics. It also offers biological drugs; oral and injectable drugs for treating cancer; specialized treatments for infectious diseases; and prescription and non-prescription drugs, including dermo-medicines, condoms, and others for retail and non-retail markets. In addition, the company provides blood-derived, biological, biotechnological, and antiretroviral drugs. It serves hospitals, private clinics, chemotherapy and hemodialysis centers, and public health institutions. The company was incorporated in 1987 and is headquartered in Cotia, Brazil.
URL
https://www.blau.com/
IPO date
Apr 19, 2021
Employees
Domiciled in
BR
Incorporated in
BR

Valuation

Title
BRL in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,754,376
27.81%
1,372,633
-2.44%
1,406,909
2.96%
Cost of revenue
1,409,394
1,177,613
991,792
Unusual Expense (Income)
NOPBT
344,982
195,020
415,117
NOPBT Margin
19.66%
14.21%
29.51%
Operating Taxes
78,364
86,742
108,068
Tax Rate
22.72%
44.48%
26.03%
NOPAT
266,618
108,278
307,049
Net income
217,206
-13.05%
249,809
-31.25%
363,368
11.73%
Dividends
(56,108)
(66,162)
(135,523)
Dividend yield
2.36%
2.29%
2.96%
Proceeds from repurchase of equity
(1,797)
(17,838)
(121,603)
BB yield
0.08%
0.62%
2.65%
Debt
Debt current
73,361
75,018
79,870
Long-term debt
527,569
571,839
260,015
Deferred revenue
Other long-term liabilities
54,458
63,195
81,829
Net debt
302,458
(25,647)
(303,762)
Cash flow
Cash from operating activities
507,203
188,060
171,903
CAPEX
(141,146)
(264,392)
(180,135)
Cash from investing activities
(314,715)
(356,774)
132,963
Cash from financing activities
(190,666)
186,095
(342,616)
FCF
312,674
(240,204)
(84,631)
Balance
Cash
492,872
407,314
643,647
Long term investments
(194,400)
265,190
Excess cash
210,753
603,872
573,302
Stockholders' equity
1,303,284
2,038,140
1,857,829
Invested Capital
2,553,321
2,063,110
1,634,503
ROIC
11.55%
5.86%
21.50%
ROCE
11.71%
6.98%
18.80%
EV
Common stock shares outstanding
180,892
177,681
179,394
Price
13.15
-19.03%
16.24
-36.41%
25.54
-25.50%
Market cap
2,378,734
-17.56%
2,885,539
-37.02%
4,581,723
-25.50%
EV
2,667,867
2,853,677
4,273,739
EBITDA
396,743
233,909
437,402
EV/EBITDA
6.72
12.20
9.77
Interest
58,314
37,583
32,431
Interest/NOPBT
16.90%
19.27%
7.81%